JP2013527246A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013527246A5 JP2013527246A5 JP2013513376A JP2013513376A JP2013527246A5 JP 2013527246 A5 JP2013527246 A5 JP 2013527246A5 JP 2013513376 A JP2013513376 A JP 2013513376A JP 2013513376 A JP2013513376 A JP 2013513376A JP 2013527246 A5 JP2013527246 A5 JP 2013527246A5
- Authority
- JP
- Japan
- Prior art keywords
- rifaximin
- crystal
- piperazine
- kappa
- theta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 106
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 claims description 76
- 229960003040 rifaximin Drugs 0.000 claims description 76
- 239000013078 crystal Substances 0.000 claims description 53
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 26
- 238000002329 infrared spectrum Methods 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 6
- 238000001757 thermogravimetry curve Methods 0.000 claims description 6
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims description 5
- 238000001237 Raman spectrum Methods 0.000 claims description 4
- 238000001179 sorption measurement Methods 0.000 claims description 4
- 239000007903 gelatin capsule Substances 0.000 claims description 3
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000008298 dragée Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000012535 impurity Substances 0.000 claims description 2
- 239000007937 lozenge Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims description 2
- 238000000371 solid-state nuclear magnetic resonance spectroscopy Methods 0.000 claims description 2
- 238000005481 NMR spectroscopy Methods 0.000 claims 1
- -1 oblate Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000001228 spectrum Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 19
- 235000012431 wafers Nutrition 0.000 description 1
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35128110P | 2010-06-03 | 2010-06-03 | |
| US61/351,281 | 2010-06-03 | ||
| US35750510P | 2010-06-22 | 2010-06-22 | |
| US61/357,505 | 2010-06-22 | ||
| US36324110P | 2010-07-10 | 2010-07-10 | |
| US61/363,241 | 2010-07-10 | ||
| US36351110P | 2010-07-12 | 2010-07-12 | |
| US61/363,511 | 2010-07-12 | ||
| US36718510P | 2010-07-23 | 2010-07-23 | |
| US61/367,185 | 2010-07-23 | ||
| US41659310P | 2010-11-23 | 2010-11-23 | |
| US61/416,593 | 2010-11-23 | ||
| PCT/US2011/039085 WO2011153444A1 (en) | 2010-06-03 | 2011-06-03 | New forms of rifaximin and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013527246A JP2013527246A (ja) | 2013-06-27 |
| JP2013527246A5 true JP2013527246A5 (enExample) | 2014-10-09 |
Family
ID=45067089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013513376A Pending JP2013527246A (ja) | 2010-06-03 | 2011-06-03 | リファキシミンの型およびその使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US8513275B2 (enExample) |
| EP (1) | EP2575464A4 (enExample) |
| JP (1) | JP2013527246A (enExample) |
| KR (1) | KR20130086338A (enExample) |
| CN (1) | CN103269587A (enExample) |
| AU (1) | AU2011261283B2 (enExample) |
| BR (1) | BR112012030783A2 (enExample) |
| CA (1) | CA2800668A1 (enExample) |
| CR (1) | CR20120620A (enExample) |
| EA (1) | EA022490B1 (enExample) |
| IL (1) | IL222900A (enExample) |
| MX (1) | MX2012013945A (enExample) |
| NZ (2) | NZ710780A (enExample) |
| PH (1) | PH12012502393A1 (enExample) |
| SG (2) | SG10201507035UA (enExample) |
| TN (1) | TN2012000533A1 (enExample) |
| WO (1) | WO2011153444A1 (enExample) |
| ZA (1) | ZA201208770B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1698630E (pt) | 2005-03-03 | 2014-09-15 | Alfa Wassermann Spa | Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais |
| US8486956B2 (en) | 2008-02-25 | 2013-07-16 | Salix Pharmaceuticals, Ltd | Forms of rifaximin and uses thereof |
| GEP20135898B (en) | 2008-02-25 | 2013-08-12 | Salix Pharmaceuticals Ltd | Rifaximin forms and usage |
| US9018684B2 (en) | 2009-11-23 | 2015-04-28 | California Institute Of Technology | Chemical sensing and/or measuring devices and methods |
| IT1398550B1 (it) | 2010-03-05 | 2013-03-01 | Alfa Wassermann Spa | Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo |
| EP2544660B1 (en) * | 2010-03-10 | 2018-06-13 | Lupin Limited | Rifaximin ready-to-use suspension |
| MX350448B (es) * | 2011-02-11 | 2017-09-07 | Salix Pharmaceuticals Ltd | Formas de rifaximina y usos de las mismas. |
| EP2705042A1 (en) * | 2011-05-02 | 2014-03-12 | Ranbaxy Laboratories Limited | Rifaximin dimethylformamide solvate |
| ITBO20110461A1 (it) | 2011-07-29 | 2013-01-30 | Alfa Wassermann Spa | Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali. |
| EP2773205B1 (en) | 2011-11-02 | 2024-05-22 | Salix Pharmaceuticals, Inc. | Rifaximin for retreating diarrhea-predominant irritable bowel syndrome |
| CA2876737A1 (en) | 2012-06-13 | 2013-12-19 | Apotex Pharmachem Inc. | Polymorphic forms of rifaximin |
| ITBO20120368A1 (it) | 2012-07-06 | 2014-01-07 | Alfa Wassermann Spa | Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso. |
| JP2015528506A (ja) * | 2012-09-13 | 2015-09-28 | サリックス ファーマスーティカルズ，インコーポレーテッド | 体重減少及び肥満の治療のためのリファキシミンの投与の方法 |
| CA2897758A1 (en) | 2013-03-15 | 2014-09-18 | Alfa Wassermann S.P.A. | Rifaximin for use in the treating of vaginal infections |
| EP2971062A2 (en) | 2013-03-15 | 2016-01-20 | ALFA WASSERMANN S.p.A. | Method for diagnosing vaginal infections |
| EA032705B1 (ru) | 2013-04-12 | 2019-07-31 | Альфасигма С.П.А. | Способ лечения или предупреждения энтеропатии |
| ITMI20131307A1 (it) * | 2013-08-02 | 2015-02-02 | A M S A Anonima Materie Sint & Affini S P A | Processo per la preparazione di refaximina k |
| ES2621557T3 (es) | 2014-03-31 | 2017-07-04 | Euticals S.P.A. | Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas |
| WO2015171493A1 (en) | 2014-05-04 | 2015-11-12 | Salix Pharmaceuticals, Inc. | Ibs microbiota and uses thereof |
| DK3546464T3 (da) | 2014-05-12 | 2020-07-27 | Alfasigma Spa | Fremstilling og anvendelse af den krystallinske form tau af rifaximin solvateret med degme |
| WO2025170483A1 (ru) * | 2024-02-07 | 2025-08-14 | Общество с ограниченной ответственностью "БИННОФАРМ ГРУПП" | Фармацевтическая композиция, обладающая антибиотической активностью |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7927613B2 (en) * | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| US7902206B2 (en) * | 2003-11-07 | 2011-03-08 | Alfa Wassermann, S.P.A. | Polymorphic forms α, β and γ of rifaximin |
| ITMI20032144A1 (it) * | 2003-11-07 | 2005-05-08 | Alfa Wassermann Spa | Forme polimorfe di rifaximina, processi per ottenerle e |
| US9682043B2 (en) * | 2003-12-09 | 2017-06-20 | Medcrystalforms, Llc | Method of preparation of mixed phase co-crystals with active agents |
| JP5017103B2 (ja) * | 2004-06-17 | 2012-09-05 | トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド | 薬剤共結晶組成物および関連した使用方法 |
| US7709634B2 (en) * | 2007-09-20 | 2010-05-04 | Apotex Pharmachem Inc. | Amorphous form of rifaximin and processes for its preparation |
| US8486956B2 (en) * | 2008-02-25 | 2013-07-16 | Salix Pharmaceuticals, Ltd | Forms of rifaximin and uses thereof |
| GEP20135898B (en) * | 2008-02-25 | 2013-08-12 | Salix Pharmaceuticals Ltd | Rifaximin forms and usage |
-
2011
- 2011-06-03 MX MX2012013945A patent/MX2012013945A/es not_active Application Discontinuation
- 2011-06-03 EA EA201270808A patent/EA022490B1/ru not_active IP Right Cessation
- 2011-06-03 US US13/152,804 patent/US8513275B2/en active Active
- 2011-06-03 SG SG10201507035UA patent/SG10201507035UA/en unknown
- 2011-06-03 WO PCT/US2011/039085 patent/WO2011153444A1/en not_active Ceased
- 2011-06-03 NZ NZ710780A patent/NZ710780A/en unknown
- 2011-06-03 PH PH1/2012/502393A patent/PH12012502393A1/en unknown
- 2011-06-03 CN CN2011800382176A patent/CN103269587A/zh active Pending
- 2011-06-03 JP JP2013513376A patent/JP2013527246A/ja active Pending
- 2011-06-03 BR BR112012030783A patent/BR112012030783A2/pt not_active Application Discontinuation
- 2011-06-03 SG SG2012082541A patent/SG185490A1/en unknown
- 2011-06-03 CA CA2800668A patent/CA2800668A1/en not_active Abandoned
- 2011-06-03 KR KR1020137000060A patent/KR20130086338A/ko not_active Ceased
- 2011-06-03 NZ NZ603590A patent/NZ603590A/en unknown
- 2011-06-03 AU AU2011261283A patent/AU2011261283B2/en active Active
- 2011-06-03 EP EP11790471.4A patent/EP2575464A4/en not_active Ceased
-
2012
- 2012-11-06 IL IL222900A patent/IL222900A/en active IP Right Grant
- 2012-11-09 TN TNP2012000533A patent/TN2012000533A1/en unknown
- 2012-11-21 ZA ZA2012/08770A patent/ZA201208770B/en unknown
- 2012-12-10 CR CR20120620A patent/CR20120620A/es unknown
-
2013
- 2013-07-31 US US13/955,660 patent/US8815888B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013527246A5 (enExample) | ||
| CA2278201C (en) | Novel modifications to 2-amino-4-(4-fluorobenzylamino)-1-ethoxycarbonyl-aminobenzene, and processes for their preparation | |
| NZ603590A (en) | New forms of rifaximin and uses thereof | |
| JP5757860B2 (ja) | 結晶形態のテノホビルジソプロキシル及びその製造方法 | |
| JP2014521726A5 (enExample) | ||
| FI3978483T3 (fi) | (S)-afoksolaneerin kiteinen tolueenisolvaatti | |
| JP2013541592A5 (enExample) | ||
| TWI632131B (zh) | 用於製備前列腺素醯胺之新穎方法 | |
| JP2007532560A5 (enExample) | ||
| CN102924424B (zh) | 一种合成盐酸多塞平的方法 | |
| KR101485522B1 (ko) | 아미노싸이올레이트를 이용한 몰리브데넘 전구체, 이의 제조방법, 및 이를 이용하여 박막을 형성하는 방법 | |
| WO2010049379A1 (en) | A process for the preparation of (r)-i -aminoindanes | |
| JP2013520488A5 (enExample) | ||
| MX2025014299A (es) | Forma solida de un compuesto de quinolina carboxamida | |
| NZ628796A (en) | Pure erlotinib | |
| NZ573212A (en) | CRYSTALLINE DULOXETINE HYDROCHLORIDE Methyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1-amine | |
| NZ598883A (en) | Crystalline forms of a parp inhibitor compound | |
| WO2013124748A4 (en) | Novel polymorphs of azilsartan medoxomil potassium | |
| TWI486346B (zh) | 噻托銨鹽（ｔｉｏｔｒｏｐｉｕｍ ｓａｌｔｓ）之新穎製法 | |
| CA2690137A1 (en) | Polymorphic and other crystalline forms of cis-ftc | |
| JP2020503330A5 (enExample) | ||
| KR101437038B1 (ko) | (+) 및 (-)-1-(3,4-디클로로페닐)-3-아자비시클로［3.1.0］헥산의 합성 방법 | |
| WO2017125941A1 (en) | An improved process for the preparation of regorafenib | |
| WO2017208251A1 (en) | A new stable polymorph of brexpiprazole and process for preparation thereof | |
| CN103755664B (zh) | 4-芳基噻（硒）唑类化合物及其用途 |